Salvage Fractionated Stereotactic Radiotherapy with or without Chemotherapy and Immunotherapy for Recurrent Glioblastoma Multiforme: A Single Institution Experience
Open Access
- 15 May 2015
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 5, 106
Abstract
Background: The current standard of care for salvage treatment of Glioblastoma Multiforme (GBM) is gross total resection and adjuvant chemoradiation for operable patients. Limited evidence exists to suggest that any particular treatment modality improves survival for recurrent GBM, especially if inoperable. We report our experience with fractionated stereotactic radiotherapy (fSRT) with and without chemo/immunotherapy, identifying prognostic factors associated with prolonged survival. Methods: From 2007 to 2014, 19 patients between 29 and 78 years old (median 55) with recurrent GBM following resection and chemoradiation for their initial tumor, received 18 – 35 Gy (median 25) in 3 – 5 fractions via Cyberknife fSRT. Clinical target volume (CTV) ranged from 0.9 to 152 cc. Sixteen patients received adjuvant systemic therapy with bevacizumab (BEV), temozolomide (TMZ), anti-epidermal growth factor receptor (125)I-mAb 425, or some combination thereof. Results: The median overall survival (OS) from date of recurrence was 8 months (2.5 – 61) and 5.3 months (0.6 – 58) from the end of fSRT. The OS at 6 and 12 months was 47% and 32%, respectively. Three of 19 patients were alive at the time of this review at 20, 49 and 58 months from completion of fSRT. Hazard ratios for survival indicated that patients with a frontal lobe tumor, adjuvant treatment with either BEV or TMZ, time to first recurrence >16 months, CTV < 36 cc, Recursive Partitioning Analysis (RPA) < 5, and ECOG (Eastern Cooperative Oncology Group) performance status < 2 were all associated with improved survival (P <0.05). There was no evidence of radionecrosis for any patient. Conclusions: Radiation Therapy Oncology Group (RTOG) 1205 will establish the role of reirradiation for recurrent GBM, however our study suggests that cyberknife with chemotherapy can be safely delivered, and is most effective in patients with smaller frontal lobe tumors, good performance status or long interval from diagnosis.Keywords
This publication has 56 references indexed in Scilit:
- New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trialsEuropean Journal of Cancer, 2012
- Radiation Therapy for the Treatment of Recurrent Glioblastoma: An OverviewCancers, 2012
- Stereotactic Body Radiation Therapy for Patients with Heavily Pretreated Liver Metastases and Liver TumorsFrontiers in Oncology, 2012
- Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?Neuro-Oncology, 2011
- Scale to Predict Survival After Surgery for Recurrent Glioblastoma MultiformeJournal of Clinical Oncology, 2010
- A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapyNeuro-Oncology, 2009
- Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastomaJournal of Neuro-Oncology, 2009
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent GlioblastomaJournal of Clinical Oncology, 2009
- Bevacizumab Plus Irinotecan in Recurrent Glioblastoma MultiformeJournal of Clinical Oncology, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005